Five women associated with Cambridge Judge Business School are named in BioBeat report on 50 top women leaders and innovators in biotech.
Five women associated with Cambridge Judge Business School are included in the sixth annual 50 Movers and Shakers in BioBusiness report announced by BioBeat, an organisation that connects entrepreneurs with leaders in biotech.
The report showcases the impact of 50 women leaders across five themes:
- science
- finance
- collaboration
- patient impact
- infrastructure.
The Entrepreneurship Centre at Cambridge Judge is a partner of BioBeat.
The five women associated with Cambridge Judge Business School are:
Charlotte Guzzo, COO and Co-founder of Sano Genetics.
The venture, which joined the Accelerate Cambridge programme at the Cambridge Judge Entrepreneurship Centre in 2017, built a software platform that allows people to access genomic data alongside cutting-edge research, and has struck key partnerships with top universities and biotech companies.
Michale Bouskila-Chubb, Head of Business Development at Healx.
The company, which repurposes existing drugs to treat rare diseases, was previously on Accelerate Cambridge. Michale developed Healx’s business model for two investment rounds totalling $10 million and $56 million.
Anna Perdrix-Rosell, CSO and Co-founder of Sixfold Bioscience.
The venture, which develops self-assembling RNA structures to precisely deliver cell and gene therapeutics, joined Accelerate Cambridge in 2016. Anna is a joint inventor of Sixfold’s drug delivery technology, which has applications in cancer and rare diseases.
Rebecca Farn, Mechanical Engineering Lead at BIOS Health.
BIOS was previously supported by the Cambridge Social Ventures programme at the Cambridge Centre for Social Innovation at Cambridge Judge. BIOS aims to put an open standard interface between the nervous system and AI into patients, which would provide more control of prosthetics.
Rebecca Kinsley, COO and Co-founder of DIOSynVax.
Rebecca was on the Entrepreneurship Centre’s EnterpriseTECH graduate programme in 2018-2019. DIOSynVax uses novel algorithms that improve the breadth of protection against multiple viruses.
BioBeat founder Miranda Weston-Smith said:
It’s a privilege to connect with these incredible leaders, discovering their work and hearing their thoughts on the direction of the industry. Their insights guide our thinking on the opportunities and challenges facing the UK life sciences sector, revealing how to harness the brightest and best ideas to make a difference for patients.